Breakthrough for AlzeCure in the development of drugs for nerve pain

AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.

AlzeCure Pharma’s CEO Martin Jönsson.

New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.

– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.

AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.

OptiCell Solutions enters a research collaboration with Karolinska Institutet

With the goal of supporting academia, healthcare, and industry in developing the cell and gene therapies of the future, OptiCell Solutions established its operations in Flemingsberg last year. The company has now entered into a research collaboration with Karolinska Institutet, marking a significant step in the desired direction.

The Park Novum inaugurated!

On November 5, the doors to The Park Novum opened – a new co-working space in Novum Research Park. The festivities came with a Halloween theme, and gathered over 150 participants who celebrated together.

Together for the medicine of the future – Karolinska ATMP Centre and ATMP Centre Uppsala strengthens collaboration in advanced therapies

A letter of intent has been signed between the Karolinska ATMP Center and the ATMP Center Uppsala to deepen collaboration in the field of advanced therapies (ATMP). The initiative was celebrated with a joint kick-off at the end of October, where hopes for new research breakthroughs and benefits for patients were in focus.